Published in Breast Cancer Res on September 29, 2011
Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes. Oncologist (2016) 1.40
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer (2013) 1.00
Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. J Hematol Oncol (2015) 0.94
Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series. Oncologist (2015) 0.94
Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse. Adv Exp Med Biol (2015) 0.83
Perspective: Not just for women. Nature (2012) 0.81
The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget (2016) 0.80
Obesity and male breast cancer: provocative parallels? BMC Med (2015) 0.80
Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. J Exp Clin Cancer Res (2015) 0.79
Occupational exposure to magnetic fields and breast cancer among Canadian men. Cancer Med (2016) 0.75
Successful use of bevacizumb and paclitaxel in a male breast cancer with liver metastases. Int J Clin Exp Med (2014) 0.75
Male papillary breast cancer treated by wide resection and latissimus dorsi flap reconstruction: A case report and review of the literature. World J Clin Oncol (2016) 0.75
Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report. BMC Res Notes (2016) 0.75
Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Sci Rep (2017) 0.75
Management of breast cancer in an Asian man with post-traumatic stress disorder: a case report. J Med Case Rep (2016) 0.75
Intracystic Papillary Carcinoma of the Breast in a Male Patient. Rare Tumors (2016) 0.75
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. Sci Rep (2016) 0.75
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Breast carcinoma in men: a population-based study. Cancer (2004) 4.88
A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet (1996) 4.38
Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet (2001) 3.75
Breast cancer in men. Ann Intern Med (2002) 3.39
Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev (2005) 3.22
Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer (2004) 2.96
Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol (2010) 2.53
EFFECT OF ORCHIDECTOMY ON SKELETAL METASTASES FROM CANCER OF THE MALE BREAST. Science (1942) 2.43
Carcinoma of the male breast. Ann Intern Med (1992) 2.27
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat (2010) 2.14
Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol (2006) 1.81
Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab (2000) 1.73
Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet (1983) 1.61
The rising incidence of male breast cancer. Breast Cancer Res Treat (2008) 1.54
Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst (2008) 1.48
Male breast cancer: is the scenario changing. World J Surg Oncol (2008) 1.45
Male breast cancer: a review of clinical management. Breast Cancer Res Treat (2006) 1.38
Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol (2001) 1.36
Lifestyle as risk factor for cancer: Evidence from human studies. Cancer Lett (2010) 1.35
Adjuvant systemic therapy for male breast carcinoma. Cancer (2005) 1.34
Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab (1993) 1.31
Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol (2009) 1.25
Linkage to BRCA2 region in hereditary male breast cancer. Lancet (1995) 1.21
The role of prolactin and growth hormone in breast cancer. Oncogene (2000) 1.20
Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol (1987) 1.14
New mechanisms for PRLr action in breast cancer. Trends Endocrinol Metab (2009) 1.08
Male breast cancer: is the incidence increasing? Ann Surg Oncol (2004) 1.08
Efficacy of anastrozole in male breast cancer. Am J Clin Oncol (2002) 1.07
Tamoxifen in the treatment of male breast carcinoma. Clin Radiol (1983) 1.05
Fulvestrant for advanced male breast cancer patients: a case series. Ann Oncol (2011) 1.04
Role of adjuvant chemotherapy in male breast cancer. Cancer (1989) 1.04
High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat (2010) 1.03
Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat (2010) 1.02
Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol (2005) 0.99
Male breast carcinoma. Can J Surg (2002) 0.98
Hormonal therapy for metastatic male breast cancer. Arch Intern Med (1983) 0.97
Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab (1996) 0.97
Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol (2005) 0.97
Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol (2000) 0.95
The experiences of men with breast cancer in the United Kingdom. Eur J Cancer (2005) 0.95
[Complete remission obtained with letrozole in a man with metastatic breast cancer]. Rev Med Interne (2004) 0.92
Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. J Endocrinol Invest (2001) 0.91
Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol (2010) 0.91
Sentinel node biopsy in male breast cancer. Nucl Med Commun (2004) 0.88
Environmental oestrogens and breast cancer: evidence for combined involvement of dietary, household and cosmetic xenoestrogens. Anticancer Res (2010) 0.88
Aromatase inhibitors and male breast cancer. Clin Transl Oncol (2007) 0.84
Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology (2008) 0.84
Fulvestrant in advanced male breast cancer. Ann Oncol (2009) 0.82
Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol (1995) 0.82
Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat (2006) 0.80
Carcinoma of the male breast: a review of adjuvant therapy. Australas Radiol (1999) 0.80
Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat (2007) 0.80
Conditions of the male breast: Gynaecomastia and male breast cancer (Review). Mol Med Rep (2011) 0.79
Problems (and solutions) in the study of male breast cancer. Rare Tumors (2010) 0.77
Highly specific sites of prolactin binding in benign and malignant breast tissue. Indian J Exp Biol (1989) 0.77
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst (2006) 7.29
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol (2005) 4.82
Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med (2011) 4.51
Choosing the right cell line for breast cancer research. Breast Cancer Res (2011) 3.57
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol (2008) 3.23
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol (2010) 2.51
Multidisciplinary team working: the emperor without clothes? Br J Hosp Med (Lond) (2012) 2.04
Breast cancer cell lines: friend or foe? Breast Cancer Res (2003) 1.98
Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res (2012) 1.97
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. Breast Cancer Res Treat (2009) 1.73
Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol (2008) 1.71
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res (2008) 1.67
Paget disease of the nipple: a multifocal manifestation of higher-risk disease. Cancer (2002) 1.65
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol (2013) 1.62
Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res (2008) 1.58
PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res (2010) 1.55
The rising incidence of male breast cancer. Breast Cancer Res Treat (2008) 1.54
Cardiac dose from tangential breast cancer radiotherapy in the year 2006. Int J Radiat Oncol Biol Phys (2008) 1.52
Breast carcinoma in women age 25 years or less. Cancer (2002) 1.50
Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol (2003) 1.43
Estrogen receptor regulation: don't forget translation. Breast Cancer Res Treat (2010) 1.39
Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.38
Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol (2008) 1.36
Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. Breast (2012) 1.27
Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist (2011) 1.21
Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol (2012) 1.13
Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res (2010) 1.12
A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat (2011) 1.12
Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat (2008) 1.11
Screening histories of invasive breast cancers diagnosed 1989-2006 in the West Midlands, UK: variation with time and impact on 10-year survival. J Med Screen (2009) 1.11
Surgery induced immunosuppression. Surgeon (2010) 1.09
Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res (2004) 1.07
MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. J Pathol (2013) 1.07
Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol (2004) 1.06
Steroid hormone receptor expression in breast cancer stroma. Breast Cancer Res Treat (2014) 1.05
Intramammary lymph node metastasis predicts poorer survival in breast cancer patients. Surg Oncol (2009) 1.05
DNA damaging effects of the dyes used in sentinel node biopsy: possible implications for clinical practice. J Surg Res (2008) 1.04
Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol (2009) 1.00
Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol (Dordr) (2012) 1.00
The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol (2002) 0.99
Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res (2008) 0.98
The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. J Clin Pathol (2012) 0.97
Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Mol Cancer (2011) 0.97
Pattern of expression of genes linked to epigenetic silencing in human breast cancer. Hum Pathol (2006) 0.97
A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. Breast Cancer Res Treat (2007) 0.96
Observer agreement comparing the use of virtual slides with glass slides in the pathology review component of the POSH breast cancer cohort study. J Clin Pathol (2012) 0.96
Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro. Int J Cancer (2006) 0.95
Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Res Treat (2010) 0.94
Patient-reported outcomes in breast oncology: a review of validated outcome instruments. Tumori (2012) 0.93
The practicalities of using tissue slices as preclinical organotypic breast cancer models. J Clin Pathol (2012) 0.93
Prognosis and pathology of screen-detected carcinomas: how different are they? Cancer (2010) 0.92
Differential regulation of oestrogen receptor β isoforms by 5' untranslated regions in cancer. J Cell Mol Med (2010) 0.92
A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. Breast Cancer Res Treat (2005) 0.92
The oligometastatic state in breast cancer: hypothesis or reality. Breast (2005) 0.91
MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol (2003) 0.91
Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat (2010) 0.91
Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. Hum Mol Genet (2002) 0.91
Surgeon and breast unit volume-outcome relationships in breast cancer surgery and treatment. Ann Surg (2013) 0.90
Shared understanding in psychiatrist-patient communication: association with treatment adherence in schizophrenia. Patient Educ Couns (2013) 0.89
Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis. Biochim Biophys Acta (2013) 0.89
Expression of oestrogen receptor beta isoforms is regulated by transcriptional and post-transcriptional mechanisms. Biochem J (2010) 0.89
ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer. Am J Pathol (2011) 0.88
The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev (2005) 0.88
Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer. PLoS One (2013) 0.85
Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. Breast Cancer Res Treat (2014) 0.85
Culture, attitude and knowledge about breast cancer and preventive measures: a qualitative study of South Asian breast cancer patients in the UK. Asian Pac J Cancer Prev (2011) 0.85
Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer. Am J Pathol (2010) 0.84
Intracellular flow cytometric analysis of primary cultured breast tumor cells. Cancer Invest (2002) 0.84
Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. J Pathol (2003) 0.83
The West Midlands breast cancer screening status algorithm - methodology and use as an audit tool. J Med Screen (2005) 0.83
The evolving role of oestrogen receptor beta in clinical breast cancer. Breast Cancer Res (2008) 0.83
CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J Pathol (2011) 0.83
Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. Clin Cancer Res (2008) 0.83
Identification of stage-specific breast markers using quantitative proteomics. J Proteome Res (2013) 0.82
Epithelial-mesenchymal interactions in breast cancer: evidence for a role of nuclear localized β-catenin in carcinoma-associated fibroblasts. Histopathology (2011) 0.82